alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 1–25 of 329 studies published 2013 · free to read (page 1 of 14) · 27,380 in the whole library · How the 0–100 score works

Download bibliography of these 329 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials

✓ Peer-reviewed alzhub usefulness score 80 out of 100. JAMA 2013-10-01

During the CEE plus MPA intervention phase, the numbers of CHD cases were 196 for CEE plus MPA vs 159 for placebo (hazard ratio [HR], 1.18; 95% CI, 0.95-1.45) and 206 vs 155, respectively, for invasive breast cancer (HR, 1.24; 95% CI, 1.01-1.53). 3 key findings →

Participants: 8,506 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Variants in the ATP-binding cassette transporter (ABCA7), apolipoprotein E ϵ4,and the risk of late-onset Alzheimer disease in African Americans

✓ Peer-reviewed alzhub usefulness score 78 out of 100. JAMA 2013-04-01

Genome-wide significance in fully adjusted models (sex, age, APOE genotype, population stratification) was observed for a SNP in ABCA7 (rs115550680, allele = G; frequency, 0.09 cases and 0.06 controls; odds ratio [OR], 1.79 [95% CI, 1.47-2.12]; P = 2.2 × 10(-9)), which is in linkage disequilibrium with SNPs previously associated with Alzheimer disease in Europeans (0.8 Conclusions and relevance In this meta-analysis of data from African American participants, Alzheimer disease was significantly associated with variants in ABCA7 and with other genes that have been associated with Alzheimer disease in individuals of European ancestry. 4 key findings →

Design: meta-analysis Participants: 5,896 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

The global prevalence of dementia: a systematic review and metaanalysis

✓ Peer-reviewed alzhub usefulness score 78 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2013-01-01

The detailed estimates in this study constitute the best current basis for policymaking, planning, and allocation of health and welfare resources in dementia care. 2 key findings →

Design: systematic review Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

The Mental Activity and eXercise (MAX) trial: a randomized controlled trial to enhance cognitive function in older adults

✓ Peer-reviewed alzhub usefulness score 78 out of 100. JAMA internal medicine 2013-05-01

Participants had a mean age of 73.4 years; 62.7% were women, and 34.9% were Hispanic or nonwhite. 5 key findings →

Design: randomized controlled trial Participants: 126 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Change in end-of-life care for Medicare beneficiaries: site of death, place of care, and health care transitions in 2000, 2005, and 2009

✓ Peer-reviewed alzhub usefulness score 76 out of 100. JAMA 2013-02-01

Our random 20% sample included 848,303 fee-for-service Medicare decedents (mean age, 82.3 years; 57.9% female, 88.1% white). 2 key findings →

Design: cohort study Participants: 270,202 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Late-life depression and risk of vascular dementia and Alzheimer's disease: systematic review and meta-analysis of community-based cohort studies

✓ Peer-reviewed alzhub usefulness score 74 out of 100. The British journal of psychiatry : the journal of mental science 2013-05-01

The present results suggest that it will be valuable to design clinical trials to investigate the effect of late-life depression prevention on risk of dementia, in particular vascular dementia and Alzheimer's disease. 2 key findings →

Design: systematic review Participants: 23 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Virgin olive oil supplementation and long-term cognition: the PREDIMED-NAVARRA randomized, trial

✓ Peer-reviewed alzhub usefulness score 74 out of 100. The journal of nutrition, health & aging 2013-01-01

A long-term intervention with an EVOO-rich MedDiet resulted in a better cognitive function in comparison with a control diet. 4 key findings →

Design: randomized controlled trial Participants: 285 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Preventing Alzheimer's disease-related gray matter atrophy by B-vitamin treatment

✓ Peer-reviewed alzhub usefulness score 74 out of 100. Proceedings of the National Academy of Sciences of the United States of America 2013-05-20

Is it possible to prevent atrophy of key brain regions related to cognitive decline and Alzheimer's disease (AD)? 3 key findings →

Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Increased expression of BIN1 mediates Alzheimer genetic risk by modulating tau pathology

✓ Peer-reviewed alzhub usefulness score 72 out of 100. Molecular psychiatry 2013-02-12

Genome-wide association studies (GWAS) have identified a region upstream the BIN1 gene as the most important genetic susceptibility locus in Alzheimer's disease (AD) after APOE. 1 key finding →

Design: meta-analysis Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Long-term health benefits of physical activity--a systematic review of longitudinal studies

✓ Peer-reviewed alzhub usefulness score 71 out of 100. BMC public health 2013-09-08

This review revealed a paucity of long-term studies on the relationship between physical activity and the incidence of NCD. 3 key findings →

Design: cross-sectional Participants: 288,724 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

A two-decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England: results of the Cognitive Function and Ageing Study I and II

✓ Peer-reviewed alzhub usefulness score 71 out of 100. Lancet (London, England) 2013-07-17

Sensitivity analyses suggest that these estimates are robust to the change in response. 2 key findings →

Participants: 2,500 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Study design of ASPirin in Reducing Events in the Elderly (ASPREE): a randomized, controlled trial

✓ Peer-reviewed alzhub usefulness score 70 out of 100. Contemporary clinical trials 2013-10-07

Cost-effective strategies to maintain healthy active lifestyle in aging populations are required to address the global burden of age-related diseases. 2 key findings →

Participants: 14,383 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Late-life depression, mild cognitive impairment, and dementia

✓ Peer-reviewed alzhub usefulness score 70 out of 100. JAMA neurology 2013-03-01

The association of depression with prevalent MCI and with progression from MCI to dementia, but not with incident MCI, suggests that depression accompanies cognitive impairment but does not precede it. 4 key findings →

Design: cohort study Participants: 2,160 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Inflammation and white matter degeneration persist for years after a single traumatic brain injury

✓ Peer-reviewed alzhub usefulness score 70 out of 100. Brain : a journal of neurology 2013-01-01

A single traumatic brain injury is associated with an increased risk of dementia and, in a proportion of patients surviving a year or more from injury, the development of hallmark Alzheimer's disease-like pathologies. 4 key findings →

Design: longitudinal study Participants: 52 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

SORL1 is genetically associated with late-onset Alzheimer's disease in Japanese, Koreans and Caucasians

✓ Peer-reviewed alzhub usefulness score 69 out of 100. PloS one 2013-04-02

To discover susceptibility genes of late-onset Alzheimer's disease (LOAD), we conducted a 3-stage genome-wide association study (GWAS) using three populations: Japanese from the Japanese Genetic Consortium for Alzheimer Disease (JGSCAD), Koreans, and Caucasians from the Alzheimer Disease Genetic Consortium (ADGC). 1 key finding →

Participants: 1,008 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Cognitive training and cognitive rehabilitation for mild to moderate Alzheimer's disease and vascular dementia

✓ Peer-reviewed alzhub usefulness score 68 out of 100. The Cochrane database of systematic reviews 2013-06-05

Overall estimates of treatment effect were calculated using a fixed-effect model, and statistical heterogeneity was measured using a standard Chi(2) statistic. 5 key findings →

Design: meta-analysis Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed